Exelixis weekly recap cites CABO sales and FDA review delay
The weekly recap says Exelixis’ CABO sales rose in RCC and NET, exclusivity extends to 2031, and the FDA pushed a colorectal combo review to March 3, 2027. It also says Exelixis paid $2.0M to Adagene for SAFEbody ADC program advancement under milestone/royalty terms.